Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization
Open accessThe DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
Abstract
A fractional dose of inactivated poliovirus vaccine (fIPV) administered by the intradermal route delivers one fifth of the full vaccine dose administered by the intramuscular route and offers a potential dose-sparing strategy to stretch the limited global IPV supply while further improving population immunity. Multiple studies have assessed immunogenicity of intradermal fIPV compared with the full intramuscular dose and demonstrated encouraging results. Novel intradermal devices, including intradermal adapters and disposable-syringe jet injectors, have also been developed and evaluated as alternatives to traditional Bacillus Calmette-Guérin needles and syringes for the administration of fIPV. Initial experience in India, Pakistan, and Sri Lanka suggests that it is operationally feasible to implement fIPV vaccination on a large scale. Given the available scientific data and operational feasibility shown in early-adopter countries, countries are encouraged to consider introducing a fIPV strategy into their routine immunization and supplementary immunization activities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The World Health Organisation (WHO) approved the use of a fractional dose of IPV (fIPV), equivalent to one-fifth of the full dose given via intramuscular injection for routine immunisation, epidemic response and supplementary immunisation activities in response to shortages of trivalent IPV that can compromise poliovirus control.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [120]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This method has been shown to be safe and effective, inducing immune responses comparable to those seen with a full dose of IPV.”
From The Fight against Poliovirus Is Not Over (2023) · cites this paper as [120]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Van Damme, P., Oosterhuis-Kafeja, F., Van der Wielen, M., Almagor, Y., Sharon, O., & Levin, Y. (2009) · Vaccine · doi:10.1016/j.vaccine.2008.10.077 · Cited by 331
Turner, N. (2009) · PubMed · Cited by 306
Intradermal vaccine delivery: Will new delivery systems transform vaccine administration?
Lambert, P. H., & Laurent, P. E. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.03.095 · Cited by 302
Fractional Doses of Inactivated Poliovirus Vaccine in Oman
Mohammed, A. J., AlAwaidy, S., Bawikar, S., Kurup, P. J., Elamir, E., Shaban, M. M. A., Sharif, S. M., van der Avoort, H. G. A. M., Pallansch, M. A., Malankar, P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909383 · Cited by 172 · cited 5×
“In the Oman study, infants received either a full intramuscular or intradermal fIPV at 2, 4, and 6 months of age, followed by a challenge dose of monovalent OPV type 1 (mOPV1) at 7 months [14].”
BackgroundMethodInfluentialSelf-citationEvaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial
Beckett, C. G., Tjaden, J., Burgess, T., Danko, J. R., Tamminga, C., Simmons, M., Wu, S.-J., Sun, P., Kochel, T., Raviprakash, K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.11.050 · Cited by 160
Resik, S., Tejeda, A., Lago, P. M., Diaz, M., Carmenates, A., Sarmiento, L., Alemañi, N., Galindo, B., Burton, A., Friede, M., et al. (2010) · The Journal of Infectious Diseases · doi:10.1086/651611 · Cited by 146 · cited 7×
“Studies assessing the ability of fIPV to boost immunity among children who had previously received OPV have been conducted in India [20], Cuba [21], and Gambia [22].”
BackgroundMethodInfluentialSelf-citationPriming after a Fractional Dose of Inactivated Poliovirus Vaccine
Resik, S., Tejeda, A., Sutter, R. W., Diaz, M., Sarmiento, L., Alemañi, N., Garcia, G., Fonseca, M., Hung, L. H., Kahn, A.-L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1202541 · Cited by 139 · cited 7×
“Studies assessing the ability of fIPV to boost immunity among children who had previously received OPV have been conducted in India [20], Cuba [21], and Gambia [22].”
BackgroundInfluentialSelf-citationBakari, M., Aboud, S. S., Nilsson, C., Francis, J. M., Buma, D. C., Moshiro, C. S., Aris, E. A., Lyamuya, E., Janabi, M., Godoy‐Ramirez, K., et al. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.08.001 · Cited by 108
Anand, A., Zaman, K., Estívariz, C. F., Yunus, M., Gary, H. E., Weldon, W. C., Bari, T. I., Steven Oberste, M., Wassilak, S. G., Luby, S. P., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.09.039 · Cited by 105 · cited 7×
“S164 • JID 2017:216 (Suppl 1) • Okayasu et al Several of these devices have been tested in clinical studies comparing intradermal fIPV with intramuscular IPV, including the disposable-syringe jet injector Tropis (PharmaJet) in Gambia [22] and the MicronJet 600 (NanoPass) disposable hollow microneedle in Bangladesh [16…”
BackgroundMethodInfluentialEstívariz, C. F., Jafari, H. S., Sutter, R. W., John, T. J., Jain, V., Agarwal, A., Verma, H., Pallansch, M. A., Singh, A. P., Guirguis, S., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70190-6 · Cited by 98 · cited 11×
“Moving forward, further assessments of the ongoing use of fIPV (eg, routine immunization in India and Sri Lanka, mass vaccination campaigns in Pakistan), as well as more pilot projects, would be helpful to facilitate country discussions and decision making to introduce fIPV.”
BackgroundInfluentialSelf-citationTroy, S. B., Kouiavskaia, D. V., Siik, J., Kochba, E., Beydoun, H. A., Mirochnitchenko, O. V., Levin, Y., Khardori, N. M., Chumakov, K., & Maldonado, Y. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu841 · Cited by 89 · cited 3×
“The use of intradermal devices requires a separate regulatory clearance (eg, 510(k) in the United States and CE Mark in the European Union), depending on the country of use.”
BackgroundHung, I. F., Levin, Y., To, K. K., Chan, K., Zhang, J., Li, P., Li, C., Xu, T., Wong, T.-Y., & Yuen, K. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.08.014 · Cited by 80
Levin, Y., Kochba, E., & Kenney, R. T. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.03.024 · Cited by 80
Affordable Inactivated Poliovirus Vaccine: Strategies and Progress
Okayasu, H., Sutter, R. W., Jafari, H. S., Takane, M., & Aylward, R. B. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiu128 · Cited by 71 · cited 1×
“To fulfill this mandate, WHO has developed a multipronged strategy to reduce the cost of IPV, which includes fIPV as one of the most promising approaches [9].”
BackgroundSelf-citationResik, S., Tejeda, A., Mach, O., Fonseca, M. C., Díaz, M., Alemañy, N., Garcia, G., Hung, L. H., Martinez, Y., & Sutter, R. W. (2014) · Vaccine · doi:10.1016/j.vaccine.2014.11.025 · Cited by 67
Self-citationSutter, R. W., Pallansch, M. A., Sawyer, L. A., Cochi, S. L., & Hadler, S. C. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44462.x · Cited by 66 · cited 1×
“Thus, the difference in antibody levels between the fIPV and intramuscular groups was not considered clinically relevant [18].”
BackgroundSelf-citationCattamanchi, A., Posavad, C. M., Wald, A., Baine, Y., Moses, J., Higgins, T. J., Ginsberg, R. S., Ciccarelli, R. B., Corey, L., & Koelle, D. M. (2008) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00167-08 · Cited by 66
Cadorna-Carlos, J., Vidor, E., & Bonnet, M.-C. (2012) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2011.10.002 · Cited by 64 · cited 4×
“These studies—conducted in Cuba [12, 13], Oman [14], Philippines [15], and Bangladesh [16]—evaluated immunogenicity by examining seroconversion rates and antibody levels following vaccination.”
BackgroundMethodInfluentialAnand, A., Molodecky, N. A., Pallansch, M. A., & Sutter, R. W. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.03.008 · Cited by 60
Self-citationRECENT STUDIES ON IMMUNIZATION AGAINST POLIOMYELITIS
SALK, J. E. (1953) · PEDIATRICS · doi:10.1542/peds.12.5.471 · Cited by 57 · cited 1×
“A study reported by Jonas Salk in 1953 using the first generation of IPV (before enhanced-potency IPV became available) concluded that polio vaccination given by both the intradermal route (using one sixth to one tenth of the standard dose) and intramuscular route demonstrated substantial immunogenicity [2].”
MethodNIRMAL, S. (1998) · Vaccine · doi:10.1016/s0264-410x(97)00293-4 · Cited by 54
Clarke, E., Saidu, Y., Adetifa, J. U., Adigweme, I., Hydara, M. B., Bashorun, A. O., Moneke-Anyanwoke, N., Umesi, A., Roberts, E., Cham, P. M., et al. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)30075-4 · Cited by 53 · cited 5×
“S164 • JID 2017:216 (Suppl 1) • Okayasu et al Several of these devices have been tested in clinical studies comparing intradermal fIPV with intramuscular IPV, including the disposable-syringe jet injector Tropis (PharmaJet) in Gambia [22] and the MicronJet 600 (NanoPass) disposable hollow microneedle in Bangladesh [16…”
BackgroundMethodInfluentialIntradermal fractional dose inactivated polio vaccine: A review of the literature
Nelson, K. S., Janssen, J. M., Troy, S. B., & Maldonado, Y. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.11.018 · Cited by 51 · cited 2×
“Despite these promising results, fIPV was not widely adopted except in Denmark, where it was the standard method of IPV vaccination in the mid-1950s [3].”
MethodImmune response to intradermally injected inactivated poliovirus vaccine
Samuel, B. U., Cherian, T., Sridharan, G., Mukundan, P., & John, T. J. (1991) · The Lancet · doi:10.1016/0140-6736(91)90480-d · Cited by 50
Bahl, S. K., Verma, H., Bhatnagar, P., Haldar, P., Satapathy, A., Kumar, K. N. A., Horton, J., Estívariz, C. F., Anand, A., & Sutter, R. W. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6533a5 · Cited by 42
Self-citationImmune response of infants to inactivated poliovirus vaccine injected intradermally
Samuel, B. U., Cherian, T., Rajasingh, J., Raghupathy, P., & John, T. J. (1992) · Vaccine · doi:10.1016/0264-410x(92)90039-m · Cited by 37
Jarrahian, C., Rein‐Weston, A., Saxon, G., Creelman, B., Kachmarik, G., Anand, A., & Zehrung, D. (2017) · Vaccine · doi:10.1016/j.vaccine.2016.11.098 · Cited by 30
Self-citationHung, I. F., Levin, Y., & To, K. K. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.12.069 · Cited by 28
Resik, S., Tejeda, A., Díaz, M., Okayasu, H., Sein, C., Molodecky, N. A., Fonseca, M. C., Alemañy, N., Garcia, G., Hung, L. H., et al. (2016) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiw492 · Cited by 24 · cited 6×
“However, recent studies among adults in Cuba [23] and among OPV-primed children aged 10 to 12 years in Sri Lanka (O.”
ResultInfluentialSelf-citationGeldenhuys, H. D., Mearns, H., Foster, J., Saxon, E. A., Kagina, B. M. N., Saganic, L., Jarrahian, C., Tameris, M. D., Dintwe, O., van Rooyen, M., et al. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.03.074 · Cited by 20 · cited 4×
“These include influenza vaccination studies using the MicronJet 600 jet injector [26–29]; studies of various investigational nucleic acid vaccines (eg, dengue, herpes simplex virus, human immunodeficiency virus) delivered by the Biojector 2000 [30–32]; BCG vaccination with the Bioject ID Pen [33]; and studies of human…”
MethodInfluentialSelf-citationSaleem, A. F., Mach, O., Yousafzai, M. T., Khan, A., Weldon, W. C., Oberste, M. S., Sutter, R. W., & Zaidi, A. K. M. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.04.075 · Cited by 18
Self-citationCirculating Vaccine-Derived Polioviruses
Kew, O. (2003) · Annual Review of Microbiology · Cited by 14
Vaccine vial stopper performance for fractional dose delivery of vaccines
Jarrahian, C., Myers, D., Creelman, B., Saxon, E. A., & Zehrung, D. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1301336 · Cited by 5 · cited 1×
“PATH recently conducted two types of tests of vial stoppers used for two WHO-prequalified IPVs following repeated piercing with a 27-gauge needle [37].”
MethodSelf-citation
Research works printed but not linked: 3
- Global Polio Eradication Initiative. Circulating vaccine-derived poliovirus. http://polioeradication.org/Dataandmonitoring/Poliothisweek/Circulatingvaccine derivedpoliovirus.aspx Accessed 20 February 2014.
- World Health Assembly. Poliomyelitis: intensification of global eradication initiative. Geneva: World Health Organization, 2012.
- Global Polio Eradication Initiative. Update on the switch and IPV supply. http://polioeradication.org/wp-content/uploads/2016/07/PPG_Mtg20160624_Presentation2.pdf Accessed 14 October 2016.
Cited by
Forster, A. H., Witham, K. L., Depelsenaire, A. C. I., Veitch, M., Wells, J. W., Wheatley, A. K., Pryor, M. J., Lickliter, J. D., Francis, B., Rockman, S., et al. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003024 · Cited by 105
Sreenivasan, N., Li, A., Shiferaw, M. L., Tran, C. H., Wallace, R. M., Blanton, J. D., Knopf, L., Abela-Ridder, B., Hyde, T. B., Siddiqi, U. R., et al. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.024 · Cited by 101
“However, recent experiences with fractional-dose inactivated polio vaccine administered intradermally have shown success in delivering vaccine on a large scale through alternative administration routes [18-20].”
Vaccination into the Dermal Compartment: Techniques, Challenges, and Prospects
Hettinga, J., & Carlisle, R. (2020) · Vaccines · doi:10.3390/vaccines8030534 · Cited by 72
End COVID-19 in low- and middle-income countries
Mobarak, A. M., Miguel, E., Abaluck, J., Ahuja, A., Alsan, M., Banerjee, A., Breza, E., Chandrasekhar, A. G., Duflo, E., Dzansi, J., et al. (2022) · Science · doi:10.1126/science.abo4089 · Cited by 68
Donadei, A., Kraan, H., Ophorst, O. J. A. E., Flynn, O., O’Mahony, C., Soema, P. C., & Moore, A. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.039 · Cited by 54
Metadata
- Authors
- Okayasu, H., Sein, C., Chang Blanc, D., Gonzalez, A. R., Zehrung, D., Jarrahian, C., Macklin, G., & Sutter, R. W.
- Affiliations
- Research, Policy and Containment, Polio Eradication Department, and
- Expanded Programme on Immunization, Immunization, Vaccines and Biologicals Department, World Health Organization, Geneva, Switzerland; and
- World Health Organization (CH)
- Program for Appropriate Technology in Health (US)
- Corresponding author
- Okayasu, Hiromasa
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-07-01
- Volume
- 216
- Issue
- suppl_1
- Pages
- S161-S167
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC5853966
- OpenAlex
- W2736278021
- Cited by
- 62
- References
- 34
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 2 · 2023: 8 · 2022: 7 · 2021: 12 · 2020: 5 · 2019: 10 · 2018: 9 · 2017: 1
- FWCI
- 8.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- inactivated poliovirus vaccine, fractional dose, intradermal administration, dose sparing, polio vaccination, vaccine supply, immunogenicity, jet injector, supplementary immunization activities, routine immunization
- MeSH terms
- Antibodies, Viral, Child, Child, Preschool, Humans, Immunization, Secondary, Infant, Injections, Intradermal, Poliovirus Vaccine, Inactivated, Poliovirus, Mass Vaccination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
